文献速递肝病消化道肿瘤与早癌

SIRT5缺失促进胆汁酸诱导的免疫抑制微环境与肝细胞癌发生

Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis.
PubMed 文献 · J Hepatol · 2022-03-12

研究通过代谢组学、基因表达谱、流式细胞术和免疫组化分析致癌基因诱导的肝细胞癌小鼠模型及人肝细胞癌样本,发现SIRT5在原发性肝细胞癌中下调,Sirt5缺陷与致癌基因协同经过琥珀酰化增加肝细胞过氧化物酶体胆汁酸合成,胆汁酸促进M2样巨噬细胞极化形成免疫抑制微环境,考来烯胺可逆转该效应。

要点

  • SIRT5在人原发性肝细胞癌样本中下调,Sirt5缺陷与致癌基因协同增加胆汁酸产生。
  • 胆汁酸作为信号介质刺激其核受体,促进M2样巨噬细胞极化,形成利于肿瘤起始细胞的免疫抑制微环境。
  • 胆汁酸螯合剂考来烯胺可逆转Sirt5缺陷促进M2样极化肿瘤相关巨噬细胞和肝脏肿瘤生长的效应。

核心结论

  • 本研究揭示了SIRT5协调胆汁酸代谢以阻止肿瘤免疫逃逸并抑制肝细胞癌发展的新功能。
  • 结果提示使用临床已验证的胆汁酸螯合剂治疗肝细胞癌患者,尤其是SIRT5降低且胆汁酸异常升高的患者,可能是一种潜在策略。

研究设计与样本

  • 研究在致癌基因诱导的肝细胞癌小鼠模型和人肝细胞癌样本中进行代谢组学分析、基因表达谱分析、流式细胞术和免疫组化分析,探讨代谢调节因子SIRT5在肝细胞癌发展中的作用。

主要发现

  • SIRT5在人原发性肝细胞癌样本中下调,小鼠Sirt5缺陷与致癌基因协同通过肝细胞过氧化物酶体过琥珀酰化和胆汁酸生物合成增加胆汁酸产生。
  • 胆汁酸作为信号介质刺激其核受体并促进M2样巨噬细胞极化,形成有利于肿瘤起始细胞的免疫抑制肿瘤微环境。
  • 肝细胞癌患者样本中高血清牛磺胆酸水平与低SIRT5表达及M2样肿瘤相关巨噬细胞增加相关。
  • 给予胆汁酸螯合剂考来烯胺可逆转Sirt5缺陷促进M2样极化肿瘤相关巨噬细胞和肝脏肿瘤生长的效应。

临床怎么用

  • 作者认为,使用临床已验证的胆汁酸螯合剂治疗肝细胞癌患者,尤其是SIRT5降低且胆汁酸异常升高的患者,可能是一种潜在策略。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The liver is a metabolically active organ and is also 'tolerogenic', exhibiting sophisticated mechanisms of immune regulation that prevent pathogen attacks and tumorigenesis. How metabolism impacts the tumor microenvironment (TME) in hepatocellular carcinoma (HCC) remains understudied. METHODS: We investigated the role of the metabolic regulator SIRT5 in HCC development by conducting metabolomic analysis, gene expression profiling, flow cytometry and immunohistochemistry analyses in oncogene-induced HCC mouse models and human HCC samples. RESULTS: We show that SIRT5 is downregulated in human primary HCC samples and that Sirt5 deficiency in mice synergizes with oncogenes to increase bile acid (BA) production, via hypersuccinylation and increased BA biosynthesis in the peroxisomes of hepatocytes. BAs act as a signaling mediator to stimulate their nuclear receptor and promote M2-like macrophage polarization, creating an immunosuppressive TME that favors tumor-initiating cells (TICs). Accordingly, high serum levels of taurocholic acid correlate with low SIRT5 expression and increased M2-like tumor-associated macrophages (TAMs) in HCC patient samples. Finally, administration of cholestyramine, a BA sequestrant and FDA-approved medication for hyperlipemia, reverses the effect of Sirt5 deficiency in promoting M2-like polarized TAMs and liver tumor growth. CONCLUSIONS: This study uncovers a novel function of SIRT5 in orchestrating BA metabolism to prevent tumor immune evasion and suppress HCC development. Our results also suggest a potential strategy of using clinically proven BA sequestrants for the treatment of patients with HCC, especially those with decreased SIRT5 and abnormally high BAs. LAY SUMMARY: Hepatocellular caricinoma (HCC) development is closely linked to metabolic dysregulation and an altered tumor microenvironment. Herein, we show that loss of the metabolic regulator Sirt5 promotes hepatocarcinogenesis, which is associated with abnormally elevated bile acids and subsequently an immunosuppressive microenvironment that favors HCC development. Targeting this mechanism could be a promising clinical strategy for HCC.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Sun R, Zhang Z, Bao R, et al. Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis. J Hepatol. 2022. PMID: 35292350. doi:10.1016/j.jhep.2022.02.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。